Download SilenciO - PROvendis

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Protein mass spectrometry wikipedia , lookup

Intrinsically disordered proteins wikipedia , lookup

Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup

Protein purification wikipedia , lookup

Proteomics wikipedia , lookup

Protein–protein interaction wikipedia , lookup

Western blot wikipedia , lookup

Polycomb Group Proteins and Cancer wikipedia , lookup

List of types of proteins wikipedia , lookup

Transcript
SilenciO
Advanced Protein Expression by Galectin-1-Silencing
Invention
Chinese Hamster ovary (CHO) cells are commonly used as a mammalian expression
system for the production of recombinant proteins. They are one of the few cell types
that can be grown at high cell density as the cells are resistant to metabolic stress.
The SilenciO-technology is a powerful tool
for the expression of non-antibody
proteins and antibodies suffering from an
initially only poor expression rate
SilenciO-technology is based on a
Galectin-1-knock down (>90%) by RNAi.
This knock down reduces the metabolic
load of the CHO expression system. The
expression level of the protein of interest
is increased by more than 1.5-fold.
Galectin-1 (Lgals-1) mRNA obtained from
Lgals1 knockdown (Lgals-kd) cells compared
to control cells
Competitive Advantages
Enabling expression of
sophisticated proteins (e.g.
complex non-antibody
proteins)
Reduction of host cell
proteins
Increased yield of viable
cells
Increased growth rate
Improved process
robustness
Application in existing cell
lines and bioprocesses
Additional experiments revealed that
using this method the yield of viable cells
during fed-batch culture experiments is
twice as high compared to control cells.
The level of host cell protein production is
reduced by SilenciO-technology.
Significant increase of antibody production
at early development stage
SilenciO-technology can be applied
afterwards in all existing cell lines
currently producing the protein with low
and very low expression rates. Thus it
enables the universal use for all protein
drug candidates which are difficult to
express and where the currently used
manufacturing process leads to high costof-goods.
Commercial Opportunities
On behalf of the University Bielefeld, PROvendis offers non-exclusive licenses for
commercial use (rights to this technology have already been granted to Boehringer
Ingelheim).
Current Status
EP and US patent applications are pending.
Further Reading
Krämer, O. (2014) RNAi-vermittelter knockdown zur Identifikation von Zielgenen für
die Verbesserung von Produktionszelllinien. Dissertation, University of Bielefeld.
Bielefeld 2014.
An invention of the University Bielefeld.
Contact:
Ref. No. 3533
Dr. Jürgen Walkenhorst
PROvendis GmbH
Schlossstr. 11-15
45468 Mülheim an der Ruhr
Germany
PROvendis GmbH is the patent licensing agency for the universities of North Rhine-Westphalia, Germany.
PROvendis recommends: www.inventionstore.de - Free e-mail service to access the latest IP-protected top technologies.
Phone:
Fax:
E-Mail:
Web:
+49 (0) 208 94 105 25
+49 (0) 208 94 105 50
[email protected]
www.provendis.info